Skip to main content
Journal cover image

Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Publication ,  Journal Article
Teng, X; Zhang, J; Han, X; Sun, J; Lam, S-K; Ai, Q-YH; Ma, Z; Lee, FK-H; Au, K-H; Yip, CW-Y; Chow, JCH; Lee, VH-F; Cai, J
Published in: Radiol Med
July 2023

PURPOSE: This study aimed to discover intra-tumor heterogeneity signature and validate its predictive value for adjuvant chemotherapy (ACT) following concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). MATERIALS AND METHODS: 397 LA-NPC patients were retrospectively enrolled. Pre-treatment contrast-enhanced T1-weighted (CET1-w) MR images, clinical variables, and follow-up were retrospectively collected. We identified single predictive radiomic feature from primary gross tumor volume (GTVnp) and defined predicted subvolume by calculating voxel-wised feature mapping and within GTVnp. We independently validate predictive value of identified feature and associated predicted subvolume. RESULTS: Only one radiomic feature, gldm_DependenceVariance in 3 mm-sigma LoG-filtered image, was discovered as a signature. In the high-risk group determined by the signature, patients received CCRT + ACT achieved 3-year disease free survival (DFS) rate of 90% versus 57% (HR, 0.20; 95%CI, 0.05-0.94; P = 0.007) for CCRT alone. The multivariate analysis showed patients receiving CCRT + ACT had a HR of 0.21 (95%CI: 0.06-0.68, P = 0.009) for DFS compared to those receiving CCRT alone. The predictive value can also be generalized to the subvolume with multivariate HR of 0.27 (P = 0.017) for DFS. CONCLUSION: The signature with its heterogeneity mapping could be a reliable and explainable ACT decision-making tool in clinical practice.

Duke Scholars

Published In

Radiol Med

DOI

EISSN

1826-6983

Publication Date

July 2023

Volume

128

Issue

7

Start / End Page

828 / 838

Location

Italy

Related Subject Headings

  • Retrospective Studies
  • Nuclear Medicine & Medical Imaging
  • Nasopharyngeal Neoplasms
  • Nasopharyngeal Carcinoma
  • Humans
  • Cisplatin
  • Chemotherapy, Adjuvant
  • Chemoradiotherapy
  • Antineoplastic Combined Chemotherapy Protocols
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Teng, X., Zhang, J., Han, X., Sun, J., Lam, S.-K., Ai, Q.-Y., … Cai, J. (2023). Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Radiol Med, 128(7), 828–838. https://doi.org/10.1007/s11547-023-01650-5
Teng, Xinzhi, Jiang Zhang, Xinyang Han, Jiachen Sun, Sai-Kit Lam, Qi-Yong Hemis Ai, Zongrui Ma, et al. “Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.Radiol Med 128, no. 7 (July 2023): 828–38. https://doi.org/10.1007/s11547-023-01650-5.
Teng, Xinzhi, et al. “Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.Radiol Med, vol. 128, no. 7, July 2023, pp. 828–38. Pubmed, doi:10.1007/s11547-023-01650-5.
Teng X, Zhang J, Han X, Sun J, Lam S-K, Ai Q-YH, Ma Z, Lee FK-H, Au K-H, Yip CW-Y, Chow JCH, Lee VH-F, Cai J. Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Radiol Med. 2023 Jul;128(7):828–838.
Journal cover image

Published In

Radiol Med

DOI

EISSN

1826-6983

Publication Date

July 2023

Volume

128

Issue

7

Start / End Page

828 / 838

Location

Italy

Related Subject Headings

  • Retrospective Studies
  • Nuclear Medicine & Medical Imaging
  • Nasopharyngeal Neoplasms
  • Nasopharyngeal Carcinoma
  • Humans
  • Cisplatin
  • Chemotherapy, Adjuvant
  • Chemoradiotherapy
  • Antineoplastic Combined Chemotherapy Protocols